B. B. Scott - Concepedia

Author

B. B. Scott

Merck & Co., Inc., Rahway, NJ, USA (United States)

Also Known As

B B Scott, B Scott, B. B. SCOTT, B. B. Scott, B. Scott, B.B. Scott

Publications

1.2K

Citations

H-Index

Concepts

All Affiliations

Merck & Co., Inc., Rahway, NJ, USA (United States)Inserm Lincoln County Hospital Scottish National Blood Transfusion Service

About

B. B. Scott is an author at Merck & Co., Inc., Rahway, NJ, USA (United States) specializing in medicine, health sciences, and immunology.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	7	7	401
2	Health Sciences	4	4	132
3	Biochemistry	2	2	79
4	Natural Sciences	1	1	23
5	Anesthesia	1	1	10

B. B. Scott

Publications

1.1K

Citations

H-Index

Page 1

	Year	Citations
Randomised controlled trial of azathioprine withdrawal in ulcerative colitis. A. B. Hawthorne, Richard F. Logan, Chris J. Hawkey, BMJ	1992	457
A Randomized, Double‐Blind, Placebo‐Controlled, Sixteen‐Week Study of Subcutaneous Golimumab in Patients With Active Nonradiographic Axial Spondyloarthritis Joachim Sieper, Désirée van der Heijde, Maxime Dougados, Arthritis & Rheumatology	2015	218
A phase IIA randomized, placebo-controlled clinical trial to study the efficacy and safety of the selective androgen receptor modulator (SARM), MK-0773 in female participants with sarcopenia Dimitris A. Papanicolaou, Shabana Ather, Hao Zhu, The journal of nutrition health & aging Hormonal ContraceptiveFemale ParticipantsMedicineAnabolic SteroidsPlacebo-controlled Clinical Trial	2013	186
Serological relationships between Escherichia coli and Salmonella smooth- and rough-mutant lipopolysaccharides as revealed by enzyme-linked immunosorbent assay for human immunoglobulin G antiendotoxin antibodies G R Barclay, B. B. Scott Infection and Immunity Pathogen DetectionBiochemistryHealthy Blood DonorsVirulence FactorPathogenesis	1987	56
TNF-α modulates angiopoietin-1 expression in rheumatoid synovial fibroblasts via the NF-κB signalling pathway B. B. Scott, Paola Zaratin, Aidan G. Gilmartin, Biochemical and Biophysical Research Communications Immune RegulationImmunologyPathologyInflammationRheumatoid Disorder	2005	47
Phase I/IIa trial of the mammalian target of rapamycin inhibitor ridaforolimus (AP23573; MK-8669) administered orally in patients with refractory or advanced malignancies and sarcoma Monica Mita, Elizabeth Poplin, Carolyn D. Britten, Annals of Oncology Phase I/iia TrialMammalian TargetOncologyHealth SciencesMedicine	2012	43
Changes in anti-endotoxin-IgG antibody and endotoxaemia in three cases of gram-negative septic shock. G R Barclay, B. B. Scott, I H Wright, PubMed InflammationEndotoxin LevelsPassive Antibody TherapyMedicineHumoral Response	1989	41
Properties of protein-chlorophyll complexes from pea (Pisum sativum L.) leaves. The organization of chlorophyll B. B. Scott, R. P. F. Gregory Biochemical Journal Plant PhysiologyBotanyMolecular BiologyPlant Molecular BiologyBiosynthesis	1975	23
Randomized, controlled trial to assess the safety and efficacy of odanacatib in the treatment of men with osteoporosis Neil Binkley, Eric Orwoll, Roland Chapurlat, Osteoporosis International Bone DiseaseOncologyBone HealthClinical TrialsPharmacotherapy	2020	18
A one‐week quadruple eradication regimen for <i>Helicobacter pylori</i> in routine clinical practice Guy Vautier, B. B. Scott Alimentary Pharmacology & Therapeutics	1997	17

Page 1